Mr. Swami Raote, B. Pharmacy, M.B.A, serves as Director at PolyNovo Limited since September 2022. He serves Entrepreneurs in Residence at DigitalDx Ventures. He serves as Chief Executive Officer at PolyNov...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Swami Raote	CEO & Director	2.3yrs	AU$1.52m	データなし
Jan-Marcel Gielen	Chief Financial Officer	5.8yrs	AU$371.95k	0.093% A$ 1.6m
David McQuillan	Chief Technical & Scientific Officer	2.1yrs	AU$538.84k	0.097% A$ 1.6m
Philip Scorgie	Chief Information Officer	1.4yrs	AU$329.02k	データなし
Ahmed Hassan	Director of Operations	2.8yrs	データなし	データなし
Lior Harel	General Counsel & Company Secretary	less than a year	データなし	データなし
Ingrid Anderson	Chief People Officer	less than a year	データなし	データなし
Edward Graubart	President of North America	5.1yrs	データなし	データなし
Joseph Amaral	Chief Medical Officer	less than a year	データなし	データなし
David Morris	President of Asia Pacific	less than a year	データなし	データなし

1.8yrs

平均在職期間

経験豊富な経営陣: PNVの経営陣は経験豊富とはみなされません ( 1.6年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Swami Raote	CEO & Director	2.1yrs	AU$1.52m	データなし
Robyn Elliott	Independent Non-Executive Director	5yrs	AU$95.00k	0.011% A$ 181.8k
Bruce Rathie	Non-Executive Independent Director	14.7yrs	AU$95.00k	0.36% A$ 6.1m
David Williams	Independent Non-Executive Chairman	10.7yrs	AU$139.43k	3.1% A$ 52.1m
Andrew Lumsden	Independent Non-Executive Director	3.3yrs	AU$95.00k	0.014% A$ 243.0k
Leon Hoare	Independent Non-Executive Director	8.8yrs	AU$95.02k	0.16% A$ 2.7m
Christine Emmanuel-Donnelly	Independent Non-Executive Director	4.4yrs	AU$95.00k	0.039% A$ 658.1k

5.0yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: PNVの取締役会は経験豊富であると考えられます ( 4.8年の平均在任期間)。

PolyNovo マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

Insufficient new directors

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Recent updates

Now 21% undervalued

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

Now 21% undervalued

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

Now 20% undervalued

Price target increased by 7.0% to AU$2.53

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 24% undervalued

Price target increased by 8.8% to AU$2.37

Consensus EPS estimates increase by 15%

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 21% undervalued

Now 23% undervalued

Now 20% undervalued

Price target increased by 9.7% to AU$2.14

When Should You Buy PolyNovo Limited (ASX:PNV)?

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Price target increased by 7.4% to AU$1.95

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Price target decreased by 9.5% to AU$1.88

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Price target decreased by 7.8% to AU$2.07

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Price target decreased by 11% to AU$2.25

Forecast breakeven date pushed back to 2025

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Price target increased by 13% to AU$2.36

Consensus EPS estimates upgraded to AU$0.0002 loss

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Forecast breakeven date pushed back to 2024

Price target increased to AU$1.98

Price target increased to AU$1.90

Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Price target increased to AU$1.68

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Consensus forecasts updated

Now 21% undervalued

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Independent Non-Executive Chairman recently bought AU$956k worth of stock

Now 23% undervalued

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

マネジメント基準チェック /34